| Description | Dehydrocorydaline chloride (13-Methylpalmatine chloride) is an alkaloid with anti-inflammatory and anti-cancer activity. Can improve the activation of p38 MAPK. |
| In vitro | 对C2C12肌母细胞处理500 nMDehydrocorydaline 可提高特定肌肉蛋白的表达水平（包括MyoD、肌原蛋白和肌球蛋白重链）。Dehydrocorydaline 处理能增强p38 MAPK的激活以及MyoD与E蛋白的相互作用。此外，Dehydrocorydaline 处理可以恢复由Cdo诱导的C2C12肌母细胞分化早期生长受体蛋白引起的分化缺陷和p38 MAPK激活。Dehydrocorydaline 显著抑制MCF-7细胞的剂量依赖性增殖，该作用可被caspase-8抑制剂Z-IETD-FMK逆转。Dehydrocorydaline 增加DNA片段但不影响ΔΨm。Western blot分析显示，Dehydrocorydaline 剂量依赖性地提高Bax蛋白表达而降低Bcl-2蛋白表达。此外，Dehydrocorydaline 诱导caspase-7、-8激活和PARP裂解但不影响caspase-9。这些结果表明，Dehydrocorydaline 通过调节Bax/Bcl-2比例，激活caspase和裂解PARP来诱导细胞凋亡，从而抑制MCF-7细胞的增殖。 |
| In vivo | Dehydrocorydaline chloride（3.6、6或10 mg/kg，腹腔注射）在乙酸诱导的扭体实验中表现出剂量依赖性的抗痛效果，并显著减轻福尔马林诱导的小鼠疼痛反应。在福尔马林实验中，Dehydrocorydaline chloride 能够减少脊髓中caspase 6（CASP6）、TNF-α、IL-1β和IL-6蛋白的表达。这证实了脱氢芸香碱对小鼠具有镇痛作用。 |
| Synonyms | 盐酸脱氢紫堇碱, 13-Methylpalmatine chloride |
| molecular weight | 401.88 |
| Molecular formula | C22H24ClNO4 |
| CAS | 10605-03-5 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year |
| Solubility | DMSO: 24 mg/mL(59.72 mM) |
| References | 1. Yoo M, et al. Dehydrocorydaline promotes myogenic differentiation via p38 MAPK activation. Mol Med Rep. 2016 Oct;14(4):3029-36. 2. Yin ZY, et al. Antinociceptive effects of dehydrocorydaline in mouse models of inflammatory pain involve the opioid receptor and inflammatory cytokines. Sci Rep. 2016 Jun 7;6:27129 3. Xu Z, et al. Dehydrocorydaline inhibits breast cancer cells proliferation by inducing apoptosis in MCF-7 cells. Am J Chin Med. 2012;40(1):177-85. |